日达仙联合化疗治疗肺癌并胸腔积液30例临床观察

目的　观察日达仙联合化疗药物胸腔内灌注对肺癌并胸腔积液的疗效。方法　采用胸腔置管引流灌注顺铂及皮下注射日达仙与单用顺铂灌注疗效对照。结果　日达仙 顺铂组患者的临床总缓解率为 76 67%。NK细胞活性及CD 4 /CD 8比值明显高于治疗前 ;单顺铂组的临床总缓解率为 46 60 %,NK细胞活性及CD 4 /CD 8比值低于治疗前。两组治疗方法有显著性差异 (P <0 0 5 )。结论　胸腔内灌注化疗药联用生物制剂日达仙 ,疗效明显优于单纯胸腔内灌注化疗药 ,并能改善临床症状 ,提高免疫功能 ,为肺癌并胸腔积液有效治疗方法之一

Combining Zadaxin and Systemic Chemotherapy in Treatment of 30 Cases of Lung Cancer with Hydrothorax

Objective To observe the therapeutic effect of combining Zadaxin and systemic chemotherapy in perfusion of thoracic cavity in the cases of lung cancer with hydrothorax Methods The sixty patients were divided into two groups: combining Zadaxin and DDP chemotherapy group and solo DDP group, both groups was treated with thoracic cavity closed drainage before perfusion Results The effective rate in treatment group was 76 67%, control group was 46 60% The expressions of NK cells activation and CD 4/CD 8 in treatment group were higher than before, those in control group were lower than before Difference was among them ( P <0 05) Conclusion Combining Zadaxin and perfusion of thoracic cavity with DDP can reach a higher response rate in patients of lung cancer with hydrothorax, better immunological function and milder side effects